Figure 15.

Sensitizing the resistant cells to the effect of erlotinib by silencing identified alternative proteins: Lipofectamine® 2000 was used for siRNA silencing of Bcl-2 in MDA-MB-231 cells with acquired resistance to erlotinib (A), and BIRC8 in MDA-MB-468 cells with acquired resistance to erlotinib (B). The LC50 values were calculated in naïve cells, naïve cells exposed to siRNA targeting the alternative protein, resistant cells, resistant cells exposed to scrambled siRNA, and resistant cells exposed to siRNA targeting the alternative protein. The LC50 values were calculated via the same sigmoidal effect (% cell death) model and are summarized in corresponding tables. The silencing of targeted alternative protein was confirmed via Western Blot for Bcl-2 and qPCR for BIRC8.